

RESEARCH

Open Access

# Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation

Reshef Tal<sup>\*</sup>, David B Seifer, Richard V Grazi and Henry E Malter

## Abstract

**Background:** Polycystic ovarian syndrome (PCOS) is characterized by increased ovarian angiogenesis and vascularity. Accumulating evidence indicates that vascular endothelial growth factor (VEGF) is increased in PCOS and may play an important role in these vascular changes and the pathogenesis of this disease. Placental growth factor (PlGF), a VEGF family member, has not been previously characterized in PCOS women. We investigated levels and temporal expression patterns of PlGF and its soluble receptor sFlt-1 (soluble Fms-like tyrosine kinase) in serum and follicular fluid (FF) of women with PCOS during controlled ovarian stimulation.

**Methods:** This was a prospective cohort study of 14 PCOS women (Rotterdam criteria) and 14 matched controls undergoing controlled ovarian stimulation. Serum was collected on day 3, day of hCG and day of oocyte retrieval. FF was collected on retrieval day. PlGF, sFlt-1 and anti-mullerian hormone (AMH) protein concentrations were measured using ELISA. Since sFlt-1 binds free PlGF, preventing its signal transduction, we calculated PlGF bioavailability as PlGF/sFlt-1 ratio.

**Results:** Serum PlGF and sFlt-1 levels were constant throughout controlled ovarian stimulation, and no significant differences were observed in either factor in PCOS women compared with non-PCOS controls at all three measured time points. However, FF PlGF levels were increased 1.5-fold in PCOS women compared with controls ( $p < 0.01$ ). Moreover, FF PlGF correlated positively with number of oocytes retrieved and the ovarian reserve marker anti-mullerian hormone (AMH) and negatively with age. In addition, FF sFlt-1 levels were decreased 1.4-fold in PCOS women compared to controls ( $p = 0.04$ ). PlGF bioavailability in FF was significantly greater (2-fold) in PCOS women compared with non-PCOS controls ( $p < 0.01$ ).

**Conclusions:** These data provide evidence that FF PlGF correlates with ovarian stimulation and that its bioavailability is increased in women with PCOS undergoing controlled ovarian stimulation. This suggests that PlGF may play a role in PCOS pathogenesis and its angiogenic dysregulation.

**Keywords:** Placental growth factor (PlGF), Soluble Fms-like tyrosine kinase (sFlt-1), Polycystic ovarian syndrome (PCOS), Angiogenesis, Ovarian stimulation

## Background

Polycystic ovarian syndrome (PCOS) is a common endocrine disorder that affects 5-7% of women of reproductive age [1]. Its cardinal features are hyperandrogenism, oligoanovulation and polycystic ovaries [1]. PCOS presents itself with a wide spectrum of manifestations which may also

include obesity, hyperlipidemia, insulin resistance, type II diabetes, and possibly cardiovascular disease [2,3].

The pathogenesis of PCOS is not well understood but accumulating evidence suggests that dysregulation of angiogenic factors may play an important role. Vascular endothelial growth factor (VEGF) is the prototypical member of a family of angiogenic factors which includes angiopoietins, placental growth factor (PlGF), basic fibroblast growth factor (bFGF) and transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1). While we and others have shown

\* Correspondence: [resheft@gmail.com](mailto:resheft@gmail.com)  
Division of Reproductive Endocrinology and Infertility, Genesis Fertility & Reproductive Medicine, Maimonides Medical Center, Brooklyn, NY, USA

angiopoietins [4], bFGF [5] and TGF- $\beta$ 1 [6,7] to be upregulated in PCOS, VEGF is the most extensively studied angiogenic factor in connection with PCOS pathophysiology [8]. VEGF is one of the major regulators of angiogenesis and its important role has been demonstrated in developmental, physiological and pathological angiogenesis [9]. It is a heparin-binding homodimeric protein of 46 kDa that consists of six isoforms, and is a potent mitogen for endothelial cells [9,10]. Its action is mediated by binding to tyrosine kinase receptors, VEGFR-1 (Fms-like tyrosine kinase: Flt-1) and VEGFR-2 (kinase domain-containing receptor: KDR/flk-1). Flt-1 is expressed in two forms via alternative splicing at the pre-mRNA level; a full-length, membrane-bound receptor, capable of transducing signal, and a truncated, soluble receptor (sFlt-1), capable of sequestering ligands or dimerizing with full-length receptors and preventing signal transduction. It has been shown that VEGF is overexpressed in the hyperthecotic ovarian stroma of polycystic ovaries (PCO) [11,12]. In addition, several investigators reported VEGF to be increased in serum and follicular fluid of PCOS women [5,13,14]. Moreover, sFlt-1, the soluble receptor for VEGF, has been shown to be decreased in serum of PCOS women undergoing controlled ovarian stimulation, contributing to increased VEGF bioavailability [15]. Several studies have demonstrated increased vascularity in the ovarian stroma of PCOS women as measured by Doppler blood flow velocities [13,16,17]. This increased ovarian vascularity was shown to correlate with increased serum VEGF levels in PCOS women [13,18], further supporting the notion that VEGF contributes to the vascular changes observed in PCO.

PlGF displays 53% homology with VEGF and is a member of the VEGF family which also includes VEGF-A, VEGF-B, VEGF-C, VEGF-D and VEGF-E. It encodes four isoforms (PlGF 1–4), composed of 131, 152, 203 and 224 amino acids after the removal of signal peptide (18 amino acids residues in length), respectively [19]. While other members of the VEGF family can bind both Flt-1 and Flk-1 receptors, PlGF binds exclusively Flt-1 receptor [20] with high affinity compared to VEGF-A and VEGF-B, the other members of the family able to specifically bind Flt-1 [21]. In cells co expressing VEGF and PlGF mRNA, a heterodimeric VEGF/PlGF protein has been described, in addition to the VEGF and PlGF homodimeric forms. This VEGF/PlGF heterodimer has been shown to promote capillary growth *in vivo* [22].

The role of PlGF in PCOS pathophysiology has not been previously investigated. We hypothesized that women with PCOS may have elevated serum and/or follicular fluid PlGF levels, which would be consistent with the increased levels seen in its family member, VEGF. Accordingly, the primary aim of our study was to investigate PlGF and sFlt-1 dynamics in serum and follicular fluid of women with PCOS as compared to women without PCOS

(serving as controls) during controlled ovarian stimulation (COS).

## Methods

### Study subjects

We prospectively enrolled 14 PCOS women from women undergoing controlled ovarian stimulation (COS) in preparation for IVF or ICSI as previously described [6]. Diagnosis of PCOS was made according to the Rotterdam consensus [23]. All 14 PCOS women had oligo- or amenorrhea and at least 12 follicles 2–9 mm in diameter per ovary. Ten of the women had hyperandrogenemia and/or hyperandrogenism, and four had normal serum androgen levels and no clinical hyperandrogenism. Secondary causes of androgen excess and anovulation were excluded. The indications for COS in the PCOS group were male factor (7 women), ovulatory dysfunction after failed superovulation induction and intrauterine inseminations (4 women) and tubal factor (3 women). Fourteen non-PCOS control women undergoing COS in preparation for IVF or ICSI were matched to PCOS women by age, BMI and use of GnRH agonist/antagonist prior to enrollment. Inclusion criteria for control non-PCOS women were normal ultrasonic ovarian morphology, normal ovulatory cycles and no endocrine abnormalities. Inclusion criteria for all study women were ages between 20–38, adequate visualization of ovaries on transvaginal ultrasound and no hormonal treatment i.e. OCPs. Exclusion criteria were diminished ovarian reserve or endometriosis. The indications for COS in the control group were male factor (9 women) or tubal factor infertility (5 women). Patient clinical characteristics are given in Table 1. This study was approved by Maimonides Medical Center institutional review board. Written informed consent was obtained from all participating women.

Women were treated using a stimulation protocol which included either down regulation using a GnRH agonist in a long protocol ( $n = 8$  for each group) or a GnRH antagonist to prevent premature ovulation ( $n = 6$  for each group). Ovarian stimulation was performed using a combination of recombinant FSH and HMG. The standard stimulation protocol was modified when there was risk of ovarian hyperstimulation or previous history of poor response. Follicular monitoring by ultrasound and blood sampling for estradiol levels were performed every 1–3 days. After the first 3–5 treatment days, the daily dose could be adjusted based on the follicular development and estradiol levels. When at least six follicles with a diameter of 16 mm were detected, either 5,000 or 10,000 IU hCG was administered, depending on the estimated risk for hyperstimulation. Oocytes were retrieved under transvaginal sonographic guided needle puncture 35 hours following hCG administration. Clinical pregnancy was defined as the presence of a gestational sac on ultrasound performed at 6 weeks after

**Table 1 Patient clinical data**

	PCOS	Non-PCOS	P value
Age (years)	30.1 ± 4.4	30.8 ± 3.7	NS
Body mass index (Kg/m <sup>2</sup> )	25.5 ± 5.6	24.9 ± 3.9	NS
Serum AMH (ng/ml)	8.0 ± 6.5	3.1 ± 1.5	0.003
Day 3 FSH (mIU/ml)	5.2 ± 1.9	6.0 ± 2.7	NS
Total gonadotropin dose (IU)	2057 ± 868	2767 ± 1786	NS
Estrogen on day of hCG (pg/ml)	2819 ± 1158	2898 ± 860	NS
No. of aspirated oocytes	17.4 ± 10.5	12.6 ± 7.2	NS
Fertilization rate (%)	67.1	64.8	NS
Clinical pregnancy rate (%)	50.0	42.9	NS

Note: PCOS, polycystic ovarian syndrome; OHSS, ovarian hyperstimulation syndrome; NS, not significant; values are given as mean ± standard deviation or percentages. P-value <0.05 was considered statistically significant.

embryo transfer. Fertilization rate was calculated as the number of fertilized oocytes divided by the number of oocytes retrieved. The clinical pregnancy rate (CPR) was calculated as the number of clinical pregnancies divided by the number of embryo transfer procedures.

#### Collection of blood and follicular fluid

Blood samples were obtained by venipuncture on cycle day 3, day of hCG administration and day of oocyte retrieval. For AMH determination, blood samples were collected within the period of 3 months prior to controlled ovarian stimulation. After collection, the blood samples were allowed to clot at room temperature for 30 min, followed by centrifugation at 1200 rpm for 10 min. Serum was stored in aliquots at -80°C until assayed. For follicular fluid collection, follicles with a diameter of >16 mm were aspirated. Only the first clear follicular fluid aspirate associated with the presence of an oocyte, without blood or flushing solution, was used for analysis. After removal of the oocyte, the fluid was centrifuged at 1200 rpm for 10 min to remove granulosa cells and debris. The supernatant was divided into aliquots and stored at -80°C until assayed.

#### PIGF, sFlt-1 and AMH ELISA assays

PIGF and sFlt-1 concentrations of serum and follicular fluid samples were determined by ELISA according to the manufacturer's protocols (R&D, Minneapolis, MN), having a sensitivity of 7.0 pg/mL and 3.5 pg/mL, respectively. The intra- and inter-assay coefficients of variation for PIGF and sFlt-1 ELISAs were 7.0% and 11.2%, and 3.2% and 5.5%, respectively. AMH concentration of serum samples was determined according to the manufacturer's protocols (Beckman and Coulter, Brea, CA). The assay sensitivity was 0.16 ng/ml. The intra- and inter-assay coefficients of variation were 4.3% and 7.4%, respectively. All assays were performed in duplicate.

#### Statistics

A power analysis powered for a two-tailed t-test was carried out prior to subject enrollment to determine the minimum required sample sizes needed to detect a 1.5-fold (assumed) statistically significant difference in growth factor between cases (PCOS) and controls. The required level of significance was at least 95% ( $p = 0.05$ ), and the required power of the test was at least 90% ( $p = 0.10$ ). Based on this calculation the required sample sizes were  $n = 14$  for each group. Data were analyzed by Student's t-test or the Mann-Whitney test, as appropriate. Results are expressed as mean ± standard error of the mean (SEM). Correlations between PIGF or sFlt-1 and various parameters were performed using Pearson correlation tests. SigmaStat (SPSS Science, Chicago, IL) was used for statistical analysis. All significance tests were two-tailed and P-value <0.05 was considered to be statistically significant.


#### Results

Clinical characteristics and data of our study subjects are shown in Table 1. As expected, PCOS women had a significantly greater serum AMH level than the non-PCOS control group ( $8.0 \pm 6.5$  ng/ml vs.  $3.1 \pm 1.5$  ng/ml,  $p = 0.003$ ) (Table 1).

Follicular fluid PIGF protein concentration on day of oocyte retrieval was increased approximately 1.5-fold in PCOS women compared with non-PCOS controls ( $58.7 \pm 19.5$  vs.  $38.6 \pm 14.0$  pg/ml, respectively,  $p = 0.006$ ) (Figure 1A). No differences were observed between PCOS and non-PCOS women in serum levels of PIGF at all three measured time points throughout controlled ovarian stimulation (Table 2).

Follicular fluid concentration of sFlt-1 was decreased 1.4-fold in PCOS compared with non-PCOS women ( $2.7 \pm 0.6$  vs.  $3.7 \pm 0.5$  ng/ml, respectively,  $p = 0.04$ ) (Figure 1B). Similarly, no differences were noted between PCOS and non-PCOS women in sFlt-1 serum levels at all three measured time points throughout controlled ovarian stimulation (Table 3). Since sFlt-1 binds PIGF, reducing its free levels and preventing its signal transduction, we calculated PIGF bioavailability as a ratio of PIGF to sFlt-1 (PIGF/sFlt-1). PIGF bioavailability in follicular fluid was significantly greater (2-fold) in PCOS women compared with non-PCOS controls (0.022 vs. 0.01, respectively,  $p < 0.01$ ) (Figure 2).

Pearson correlation analysis was performed to evaluate for correlations between PIGF or sFlt-1 concentration and various stimulation cycle parameters. Follicular fluid PIGF correlated positively with number of oocytes retrieved ( $r = 0.41$ ,  $p = 0.03$ ) and AMH ( $r = 0.60$ ,  $p = 0.001$ ), and inversely with age ( $r = -0.38$ ,  $p = 0.04$ ) (Figure 3). Follicular fluid PIGF was not found to correlate with total gonadotropin dose administered ( $r = -0.29$ ,  $p = 0.15$ ), peak estrogen level ( $r = 0.16$ ,  $p = 0.43$ ) or day 3 FSH ( $r = 0.09$ ,  $p = 0.66$ ). With regards to stimulation



cycle outcomes, no correlation was found between follicular fluid PIGF and fertilization rate ( $r = -0.20$ ,  $p = 0.34$ ). Moreover, no difference was noted in follicular fluid PIGF level between pregnant and non-pregnant women (49.8 vs. 43.8 pg/ml,  $p = \text{NS}$ ). No correlations were found between follicular fluid sFlt-1 and either age, AMH, day 3 FSH, total gonadotropin dose, peak estrogen level, number of oocytes retrieved, fertilization rate or clinical pregnancy rate (data not shown).

## Discussion

This study is the first to report levels of PIGF in serum and follicular fluid of women with PCOS undergoing controlled ovarian stimulation. These data demonstrate that follicular fluid PIGF concentration is increased while concentration of its soluble receptor sFlt-1 is decreased, resulting in increased PIGF bioavailability in women with PCOS. In addition, this study provides the first evidence that follicular fluid PIGF is associated with serum AMH and number of aspirated oocytes.

VEGF has been shown to be increased in ovarian tissue [11,12] as well as serum and follicular fluid [5,13-15] of PCOS women compared with non-PCOS controls. In addition, sFlt-1, the soluble receptor for VEGF and PIGF, has been reported to be decreased in serum and follicular fluid of PCOS women undergoing controlled ovarian

stimulation, contributing to increased VEGF bioavailability [15]. The increased serum VEGF levels in PCOS were shown to correlate with increased ovarian vascularity in these women [13,18], while laparoscopic ovarian drilling has been shown to reduce Doppler indices of ovarian stromal blood flow [24] with a concomitant reduction in circulating VEGF levels [25], supporting the notion that VEGF contributes to the vascular changes observed in PCO. Our results demonstrate that follicular fluid PIGF, another important VEGF family member, is increased in PCOS and suggest a role for PIGF overactivity in the pathogenesis of PCOS. Additional research is warranted to investigate the relative contribution of PIGF to the increased ovarian vascularity and pathophysiology of PCOS. In contrast to VEGF, which is increased in both serum and follicular fluid of PCOS women [5,13-15], PIGF was not increased in serum of PCOS women in our study. This difference may be due to increased VEGF production in PCOS by non-ovarian sources. In support of this, obesity and insulin resistance, which are closely associated with PCOS, are characterized by VEGF overproduction by adipose, vascular and bone-marrow derived cells [26,27]. An alternative explanation for the increased serum VEGF, but not serum PIGF, in PCOS women may be increased ovarian production of VEGF relative to PIGF. However, the follicular fluid:serum ratio of PIGF was found to be 4 to 6 fold in our study, which is comparable to previously reported follicular fluid:serum

**Table 2 Serum PIGF (pg/ml) in PCOS and non-PCOS women during controlled ovarian stimulation**


Group	Day 3	hCG	Oocyte retrieval
PCOS	9.6 ± 1.1	10.7 ± 1.4	10.1 ± 1.9
Control	9.7 ± 1.4	10.8 ± 2.0	10.1 ± 2.0

Note: PCOS, polycystic ovarian syndrome; values are mean ± standard deviation.

**Table 3 Serum sFlt-1 (ng/ml) in PCOS and non-PCOS women during controlled ovarian stimulation**

Group	Day 3	hCG	Oocyte retrieval
PCOS	55.9 ± 9.3	56.3 ± 7.9	57.2 ± 10.7
Control	58.1 ± 8.0	57.6 ± 7.4	55.2 ± 8.6


Note: PCOS, polycystic ovarian syndrome; values are mean ± standard deviation.



ratio of VEGF (3 to 4 fold) [5], making this explanation less likely.

AMH, or mullerian-inhibiting substance (MIS), is widely considered a highly sensitive marker of ovarian reserve, and has been shown to correlate with ovarian response to stimulation during ART, as well as the risk of OHSS [28,29]. In addition, AMH correlates inversely with age, and its levels become undetectable in the serum of menopausal women [30]. Our results revealed that follicular fluid PIGF correlated positively with serum AMH and number of oocytes retrieved while it correlated inversely with age, suggesting that follicular fluid PIGF, similarly to AMH, may be associated with ovarian response to stimulation. While no studies, to the best of our knowledge, have previously reported on associations between follicular fluid PIGF and ART cycle stimulation/outcomes, previous observations showed that follicular fluid VEGF correlates positively with age and negatively with number of oocytes retrieved and pregnancy rates [31,32]. These data suggest that PIGF and VEGF, while belonging to the same VEGF family, may have different biological roles in the local ovarian microenvironment. Further studies are needed to confirm our data and investigate potential associations between PIGF and ART outcomes.

Several lines of evidence indicate that PIGF is a potent pro-angiogenic factor which contributes to pathological angiogenesis. PIGF and VEGF have been demonstrated to have similar potency in stimulating tissue factor production and chemotaxis in monocytes [33]. In addition, PIGF has been shown to stimulate angiogenesis and collateral growth in ischemic heart and limb with efficiency at least comparable to VEGF [34]. Moreover, Suzumori et al. have reported that PIGF concentration is increased in peritoneal fluid of women with endometriosis, and suggested that it may contribute to the pathological neovascularization



characteristic of endometriotic lesions [35]. Since VEGF is considered a key mediator of ovarian hyperstimulation syndrome (OHSS) by increasing vascular permeability, its overexpression in PCOS has been suggested to contribute to the increased risk of OHSS seen in these patients [36]. As the risk of OHSS is known to be greater in women receiving GnRH agonist protocol as compared to GnRH antagonist protocol, we matched PCOS women to non-PCOS women according to study protocol, eliminating this potential bias. In our study, follicular fluid PIGF was increased in

PCOS and positively correlated with the number of oocytes retrieved i.e. ovarian stimulation. Thus, it is interesting to speculate whether PIGF may play a similar role to VEGF in OHSS. Indeed, transgenic mice overexpressing PIGF in skin under the control of keratin-14 promoter showed a substantial increase in number, branching and size of dermal blood vessels, together with enhanced vascular leakiness [37], while inhibition of PIGF was associated with reduced plasma extravasation in pathological conditions [38]. Moreover, the gonadotropin LH, which is well-known to stimulate VEGF leading to OHSS [39], has been shown to increase the follicular fluid PIGF/sFlt-1 ratio in women undergoing ovarian stimulation [40]. Further studies are needed to evaluate the potential role of PIGF in OHSS pathogenesis and examine its utility as a predictor for early and/or late OHSS.

In the current study, PIGF concentration was 4 to 6-fold greater in follicular fluid compared with serum, suggesting that the ovary is the primary site of production of follicular fluid PIGF. Consistent with our data, Gutman et al. reported higher levels of PIGF in follicular fluid compared with plasma (where levels were undetectable) in women undergoing IVF [40]. A possible explanation for the differences in ability to measure PIGF in the circulation between the studies is the different type of sample medium used (i.e. serum vs. plasma). Follicular fluid is the product of diffusion of blood constituents across the blood-follicle barrier and of molecules secreted by granulosa and theca cells. Although it is unknown which ovarian compartment may be responsible for PIGF production, there is a strong body of evidence that ovarian granulosa and endothelial cells are the main source of production of VEGF during hyperstimulation [36,41], and it is reasonable to hypothesize that PIGF is produced by similar mechanisms. In-vitro and animal experiments are needed to clarify this point further.

## Conclusions

This is the first study to characterize serum and/or follicular fluid levels of PIGF in PCOS during controlled ovarian stimulation. Our study provides evidence that follicular fluid PIGF correlates with ovarian stimulation and that its bioavailability, as measured by the PIGF/sFlt-1 ratio, is increased in women with PCOS. Results of this study suggest that PIGF may play a role in the angiogenic dysregulation characteristic of PCOS and its predisposition to OHSS. Further studies are warranted to investigate these possibilities.

## Competing interests

RT has nothing to disclose. DBS receives royalties from license of a patent between University of Medicine and Dentistry of New Jersey/Massachusetts General Hospital and Beckman Coulter for use of anti-mullerian hormone in assessing ovarian reserve; is a consultant to Univfy; and is a medical advisor of Women's Intergrated Network. RVG has nothing to disclose. HEM has nothing to disclose.

## Authors' contributions

RT conceived and designed the study, performed the ELISA experiments and statistical analysis, and drafted the manuscript. DBS designed the study and edited the manuscript. RVG edited the manuscript. HEM helped with study design and performed patient sample collection. All authors read and approved the final manuscript.

## Acknowledgements

The authors thank Dr. Howard Minkoff for scientific advice. We thank Dr. Dan Eshel for using his lab facilities and Dr. Theodore Muth for microplate ELISA reader. We also thank Cindy Ammirabile for her help with patient recruitment. This work was supported by a grant from Maimonides Medical Center Research and Development Foundation (RT, DBS). The work was presented in part on March 21, 2013 at the Society for Gynecologic Investigation (SGI) 60<sup>th</sup> Annual Scientific Meeting, Orlando, Florida.

Received: 13 May 2014 Accepted: 15 August 2014

Published: 20 August 2014

## References

1. Norman RJ, Dewailly D, Legro RS, Hickey TE: Polycystic ovary syndrome. *Lancet* 2007, **370**:685–697.
2. Padmanabhan V: Polycystic ovary syndrome—"A riddle wrapped in a mystery inside an enigma". *J Clin Endocrinol Metab* 2009, **94**:1883–1885.
3. Qiao J, Feng HL: Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. *Hum Reprod Update* 2011, **17**:17–33.
4. Tal R, Seifer DB, Grazi RV, Malter HE: Angiopoietin-1 and angiopoietin-2 are altered in polycystic ovarian syndrome (PCOS) during controlled ovarian stimulation. *Vasc Cell* 2013, **5**:18.
5. Artini PG, Monti M, Matteucci C, Valentino V, Cristello F, Genazzani AR: Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation. *Gynecol Endocrinol* 2006, **22**:465–470.
6. Tal R, Seifer DB, Shohat-Tal A, Grazi RV, Malter HE: Transforming growth factor-beta1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation. *Fertil Steril* 2013, **100**:538–543.
7. Raja-Khan N, Kunselman AR, Demers LM, Ewens KG, Spielman RS, Legro RS: A variant in the fibrillin-3 gene is associated with TGF-beta and inhibin B levels in women with polycystic ovary syndrome. *Fertil Steril* 2010, **94**:2916–2919.
8. Peitsidis P, Agrawal R: Role of vascular endothelial growth factor in women with PCO and PCOS: a systematic review. *Reprod Biomed Online* 2010, **20**:444–452.
9. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. *Endocr Rev* 1997, **18**:4–25.
10. Charnock-Jones DS, Sharkey AM, Rajput-Williams J, Burch D, Schofield JP, Fountain SA, Boock CA, Smith SK: Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. *Biol Reprod* 1993, **48**:1120–1128.
11. Ferrara N, Frantz G, LeCouter J, Dillard-Telm L, Pham T, Draksharapu A, Giordano T, Peale F: Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. *Am J Pathol* 2003, **162**:1881–1893.
12. Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. *Am J Pathol* 1995, **146**:157–165.
13. Agrawal R, Sladkevicius P, Engmann L, Conway GS, Payne NN, Bekis J, Tan SL, Campbell S, Jacobs HS: Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. *Hum Reprod* 1998, **13**:651–655.
14. Amin AF, Abd el-Aal DE, Darwish AM, Meki AR: Evaluation of the impact of laparoscopic ovarian drilling on Doppler indices of ovarian stromal blood flow, serum vascular endothelial growth factor, and insulin-like growth factor-1 in women with polycystic ovary syndrome. *Fertil Steril* 2003, **79**:938–941.

15. Artini PG, Ruggiero M, Parisen Toldin MR, Monteleone P, Monti M, Cela V, Genazzani AR: **Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF.** *Hum Fertil (Camb)* 2009, **12**:40–44.
16. Battaglia C, Artini PG, D'Ambrogio G, Genazzani AD, Genazzani AR: **The role of color Doppler imaging in the diagnosis of polycystic ovary syndrome.** *Am J Obstet Gynecol* 1995, **172**:108–113.
17. Zaidi J, Campbell S, Pittrof R, Kyei-Mensah A, Shaker A, Jacobs HS, Tan SL: **Ovarian stromal blood flow in women with polycystic ovaries—a possible new marker for diagnosis?** *Hum Reprod* 1995, **10**:1992–1996.
18. Abd El Aal DE, Mohamed SA, Amine AF, Meki AR: **Vascular endothelial growth factor and insulin-like growth factor-1 in polycystic ovary syndrome and their relation to ovarian blood flow.** *Eur J Obstet Gynecol Reprod Biol* 2005, **118**:219–224.
19. De Falco S: **The discovery of placenta growth factor and its biological activity.** *Exp Mol Med* 2012, **44**:1–9.
20. Park JE, Chen HH, Winer J, Houck KA, Ferrara N: **Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.** *J Biol Chem* 1994, **269**:25646–25654.
21. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U: **Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells.** *Proc Natl Acad Sci U S A* 1998, **95**:11709–11714.
22. Cao Y, Chen H, Zhou L, Chiang MK, Anand-Apte B, Weatherbee JA, Wang Y, Fang F, Flanagan JG, Tsang ML: **Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR.** *J Biol Chem* 1996, **271**:3154–3162.
23. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group: **Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).** *Hum Reprod* 2004, **19**:41–47.
24. Parsanezhad ME, Bagheri MH, Alborzi S, Schmidt EH: **Ovarian stromal blood flow changes after laparoscopic ovarian cauterization in women with polycystic ovary syndrome.** *Hum Reprod* 2003, **18**:1432–1437.
25. El Behery MM, Diab AE, Mowafy H, Ebrahiem MA, Shehata AE: **Effect of laparoscopic ovarian drilling on vascular endothelial growth factor and ovarian stromal blood flow using 3-dimensional power Doppler.** *Int J Gynaecol Obstet* 2011, **112**:119–121.
26. Fain JN: **Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells.** *Vitam Horm* 2006, **74**:443–477.
27. Cao Y: **Angiogenesis and vascular functions in modulation of obesity, adipose metabolism, and insulin sensitivity.** *Cell Metab* 2013, **18**:478–489.
28. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artesisio AC, Stabile G, Volpe A: **Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).** *Hum Reprod Update* 2010, **16**:113–130.
29. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Sheldon RM: **Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles.** *Fertil Steril* 2002, **77**:468–471.
30. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BC, Themmen AP: **Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment.** *Mol Hum Reprod* 2004, **10**:77–83.
31. Friedman CI, Danforth DR, Herbosa-Encarnacion C, Arbogast L, Alak BM, Seifer DB: **Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction.** *Fertil Steril* 1997, **68**:607–612.
32. Friedman CI, Seifer DB, Kennard EA, Arbogast L, Alak B, Danforth DR: **Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential.** *Fertil Steril* 1998, **70**:836–839.
33. DiSalvo J, Bayne ML, Conn G, Kwok PW, Trivedi PG, Soderman DD, Palisi TM, Sullivan KA, Thomas KA: **Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer.** *J Biol Chem* 1995, **270**:7717–7723.
34. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Compennolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, Carmeliet P: **Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.** *Nat Med* 2002, **8**:831–840.
35. Suzumori N, Sugiura-Ogasawara M, Katano K, Suzumori K: **Women with endometriosis have increased levels of placental growth factor in the peritoneal fluid compared with women with cystadenomas.** *Hum Reprod* 2003, **18**:2595–2598.
36. Soares SR, Gomez R, Simon C, Garcia-Velasco JA, Pellicer A: **Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.** *Hum Reprod Update* 2008, **14**:321–333.
37. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L, Failla CM, Zambruno G: **Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability.** *J Cell Sci* 2002, **115**:2559–2567.
38. Carmeliet P, Moons L, Luttun A, Vincenti V, Compennolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, VandenDriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG: **Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.** *Nat Med* 2001, **7**:575–583.
39. Gomez R, Lima I, Simon C, Pellicer A: **Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats.** *Reproduction* 2004, **127**:483–489.
40. Gutman G, Barak V, Maslovitz S, Amit A, Lessing JB, Geva E: **Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis.** *Fertil Steril* 2008, **89**:922–926.
41. Rizk B, Aboulghar M, Smitz J, Ron-El R: **The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.** *Hum Reprod Update* 1997, **3**:255–266.

doi:10.1186/1477-7827-12-82

**Cite this article as:** Tal et al.: Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation. *Reproductive Biology and Endocrinology* 2014 **12**:82.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

